Premium
Nalbuphine combined with midazolam for outpatient sedation
Author(s) -
SURY M. R. J.,
COLE P. V.
Publication year - 1988
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/j.1365-2044.1988.tb08973.x
Subject(s) - nalbuphine , medicine , midazolam , sedative , anesthesia , sedation , respiratory system , depression (economics) , opioid , receptor , economics , macroeconomics
Summary Eighteen healthy volunteers were studied in a double‐blind trial to determine which dose of nalbuphine (0.05, 0.1 or 0.2 mg/kg) may be combined with midazolam 0.05 mg/kg to provide a safe outpatient intravenous sedative technique. The ventilatory response to carbon dioxide and end tidal Pco 2 were measured before and after the drugs were administered. A mild degree of respiratory depression occurred, which was maximal at 3–30 minutes after injection. This was not related to dose except that nalbuphine 0.05 mg/kg resulted in the slowest respiratory rates. The implications of these findings for clinical practice are discussed.